86 studies found for:    myotonic dystrophy | Interventional Studies
Show Display Options
Rank Status Study
1 Active, not recruiting Observational Prolonged Trial in Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention: Behavioral: Behavioural change intervention
2 Recruiting Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy
Interventions: Drug: Mexiletine;   Drug: Placebo
3 Completed Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients
Condition: Myotonic Dystrophy
Intervention: Other: Supine spirometry
4 Completed Efficacy and Safety of DHEA for Myotonic Dystrophy
Condition: Myotonic Dystrophy
Intervention: Drug: dehydroepiandrosterone 100 and 400 mg
5 Unknown  RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Conditions: Myotonic Dystrophy;   Sudden Cardiac Death
Interventions: Procedure: Electrophysiological study;   Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant
6 Recruiting A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: IONIS-DMPKRx;   Drug: Placebo
7 Active, not recruiting A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Condition: Breast Cancer
Interventions: Drug: T-DM1;   Drug: Trastuzumab
8 Completed Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients
Condition: DM1
Intervention: Other: Clinical examination, skin biopsy, blood and urine sampling
9 Recruiting A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Neratinib;   Drug: T-DM1
10 Recruiting Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
Condition: Advanced Breast Cancer
Intervention: Drug: PD-0332991 and T-DM1
11 Active, not recruiting A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Condition: HER2 Positive Breast Cancers
Interventions: Drug: ONT-380;   Drug: T-DM1
12 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
13 Completed
Has Results
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
Condition: Myotonic Dystrophy
Intervention: Drug: SomatoKine/IPLEX
14 Completed
Has Results
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Biological: pertuzumab;   Biological: Trastuzumab emtansine [Kadcyla]
15 Recruiting T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Trastuzumab emtansine
16 Completed
Has Results
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
17 Completed Methylphenidate in Myotonic Dystrophy Type 1
Condition: Dystrophia Myotonica 1
Interventions: Drug: Methylphenidate;   Drug: Placebo
18 Unknown  Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: rhIGF-I/rhIGFBP-3;   Drug: placebo
19 Recruiting Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy
Condition: Myopathy
Intervention: Device: Nocturnal ventilation
20 Unknown  Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years